Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. Show more

Location: 828 Winter Street, Waltham, MA, 02451, United States | Website: https://xiliotx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

35.89M

52 Wk Range

$0.62 - $1.70

Previous Close

$0.69

Open

$0.69

Volume

147,392

Day Range

$0.68 - $0.70

Enterprise Value

-46.0M

Cash

89.07M

Avg Qtr Burn

N/A

Insider Ownership

45.76%

Institutional Own.

22.99%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.